A Microbicide is any substance or process that kills germs (bacteria, viruses, and other microorganisms that can cause infection and disease). Also called germicide.
An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organizers say.
Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.
Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.
In a recent study, researchers at the Public Health Agency of Canada found that dry fog fumigation using peracetic acid (PAA) completely deactivated SARS-CoV-2 on all nine of their test surfaces.
The nonprofit International Partnership for Microbicides is pleased to announce the World Health Organization's prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.
Drugs currently used to keep the HIV virus in check also cause immune-system changes that might make humans better able to resist viral infections – but might also cause harmful inflammation, according to a study published today in Cell Reports Medicine.
The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.
The International Partnership for Microbicides today welcomed a positive opinion from the European Medicines Agency on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection.
A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
Researchers in Italy have found that it is possible to completely inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using short-wavelength UV (UV-C) irradiation.
A woman who is eight-months pregnant is the first participant to be enrolled into a study evaluating the safety and acceptability of two different HIV prevention approaches when used during pregnancy -- the monthly dapivirine vaginal ring, which is currently under regulatory review, and a daily antiretroviral (ARV) pill called Truvada, an approach already approved in several countries and commonly referred to as PrEP, short for pre-exposure prophylaxis.
The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa.
In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling.
A vaginal microbicide that could prevent sexual transmission of HIV-1 in women has tremendous potential for saving lives and helping staunch an epidemic.
A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.
AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.
University at Buffalo researchers received an $880,000 grant to help quicken the development of generic equivalents of contraceptives and other drugs delivered vaginally or to the uterus, such as by intrauterine devices
The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models.
As incredible as it sounds, a rice paddy field could one day yield an inexpensive way to prevent HIV.
The nonprofit International Partnership for Microbicides announced today the start of the first clinical trial of vaginal rings designed to slowly release the antiretroviral drug dapivirine over three months to prevent HIV in women.